

#### **TCTAP 2024**

# Clinical Use of Intracoronary Imaging Guidance and Optimization of Coronary Interventions

Evelyn Regar, MD, PhD, FESC LMU Hospital, Munich, Germany




#### **Disclosure**

Evelyn Regar serves as medical advisor for


- Zed-Medical Inc, Livermore, CA, USA
- Kaminari Medical BV, Rotterdam, The Netherlands



### Clinical Use of Intracoronary Imaging Current Guidelines: Moderate Class Ila Recommendations



2021 ACC/AHA/SCAI Coronary Revascularization Guidelines



**2023** ESC Guidelines for the management of ACS



# Clinical Use of Intracoronary Imaging Updated Concepts 2024: Strong Recommendations



"In fact, given the abundance of data from multiple randomized controlled trials and meta-analyses supporting better clinical outcomes with imaging-guided PCI, especially through IVUS, we believe that not providing a higher class of recommendation for this strategy might be considered as a

### missed opportunity

in this document"



### Clinical Use of Intracoronary Imaging Updated Concepts 2024: Strong Recommendations



"As such, it is time for the scientific community to acknowledge and embrace the consistent and convincing evidence favoring the routine use of intracoronary imaging"

## Clinical Use of Intracoronary Imaging Updated Concepts 2024: Evidence & 30 Years of Experience!





# Clinical Use of Intracoronary Imaging Updated Concepts 2024: Evidence & 30 Years of Experience!



#### **Clearly defined goal:**

Optimal flow conditions through the vessel

- Optimal stent expansion
- Optimal stent position
- No residual vessel damage

## Clinical Use of Intracoronary Imaging Updated Concepts 2024: Evidence & 30 Years of Experience!

#### **IMPROVE Trial**

The <u>IMP</u>act on <u>Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and <u>Economic impact</u> (IMPROVE) trial: Study design and rationale</u>



Evan Shlofmitz, DO, <sup>a</sup> Rebecca Torguson, MPH, <sup>a</sup> Gary S. Mintz, MD, <sup>a</sup> Cheng Zhang, PhD, <sup>a</sup> Andrew Sharp, MD, <sup>b</sup> John McB. Hodgson, MD, <sup>c</sup> Binita Shah, MD, <sup>d</sup> Gautam Kumar, MD, <sup>c</sup> Jasvindar Singh, MD, <sup>f</sup> Becky Inderbitzen, MSE, <sup>g</sup> William S. Weintraub, MD, <sup>a</sup> Hector M. Garcia-Garcia, MD, PhD, <sup>a</sup> Carlo Di Mario, MD, <sup>b</sup> and Ron Waksman, MD <sup>a</sup> DC, OH, NY, GA, MO, USA; Cardiff, United Kingdom; Amsterdam, Netberlands; and Florence, Italy

Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent major adverse cardiovascular events after PCI. However, IVUS utilization remains low. An increasing number of high-risk or complex coronary artery lesions are treated with PCI, and we hypothesize that the impact of IVUS in guiding treatment of these complex lesions will be of increased importance in reducing major adverse cardiovascular events while remaining cost-effective. The "IMPact on Revoscularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact" trial (registered on clinicaltrials.gov: NCT04221815) is a multicenter, international, clinical trial randomizing subjects to IVUS-guided versus angiography-guided PCI in a 1:1 ratio. Patients undergoing PCI involving a complex lesion are eligible for enrollment. Complex lesion is defined as involving at least 1 of the following characteristics: chronic total occlusion, in-stent restenosis, severe coronary artery calcification, long lesion (228 mm), or bifurcation lesion. The clinical investigation will be conducted at approximately 120 centers in North America and Europe, enrolling approximately 2,500 to 3,100 randomized subjects with an adaptive design. The primary clinical end point is the rate of target vessel failure at 12 months, defined as the composite of cardiac death, target vessel-related myocardial infarction, and ischemic-driven target vessel revascularization. The co-primary imaging end point is the final post-PCI minimum stent area assessed by IVUS. The primary objective of this study is to assess the impact of IVUS guidance on the PCI treatment of complex lesions. (Am Heart J 2020;228:65-71.)

Shlofmitz E et al. Am Heart J 2020, 228, 65-71

### Optimal Stent Deployment is achieved if on final IVUS the following 3 criteria have been met:


- minimal stent area MSA >90% of distal reference lumen area
- absence of geographic miss, defined as plaque burden >50% within 5 mm from the proximal or distal stent edge, or both
- no edge dissection involving the media with arc ≥60° and length ≥3 mm



# Clinical Use of Intracoronary Imaging Updated Concepts 2024: Evidence & 30 Years of Experience!


### Know-How to achieve the goal: Optimal flow conditions through the vessel

- Image upfront
- Define PCI strategy accordingly
- Execute PCI strategy
- Document result, optimize if necessary




# Clinical Use of Intracoronary Imaging Updated Concepts 2024: Evidence & 30 Years of Experience!

80% impact on stent deployment is gained by upfront imaging!



Angiogram








Angiogram and QCA measurements






Functional assessment with FFR



What to treat: FFR




Assess lesion- and plaque characteristics









Assess lesion- and plaque characteristics



Assess lesion- and plaque characteristics






































Select "landing zones"








Position of proximal LZ on crosssectional OCT image.




Match proximal stent marker to OCT-position.








Position of proximal LZ on crosssectional OCT image.




Direct stenting DES 3.0x38mm








Position of proximal LZ on crosssectional OCT image.







Position of proximal LZ on crosssectional OCT image.




Post dilatation with 3.0x15mm NC balloon





Stent implantation: assess result





## Clinical Use of Intracoronary Imaging Conclusion

- There is vast evidence, that intracoronary imaging reduces hard clinical endpoints
- There is vast experience, how to use intracoronary imaging
- Use intracororary imaging upfront, before stent implantation, in order to define
  - Lesion characteristics & length
  - Reference segments and diameters
  - Stent diameter & length
  - Need for lesion preparation
  - Need for postdilatation
- Use Intracorornary imgaging to document result and optimize, if necessary

